Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CRVO 
CervoMed Inc. (CRVO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/28/2025: CRVO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $22.43
1 Year Target Price $22.43
| 5 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 158.69% | Avg. Invested days 32 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 91.97M USD | Price to earnings Ratio - | 1Y Target Price 22.43 |
Price to earnings Ratio - | 1Y Target Price 22.43 | ||
Volume (30-day avg) 7 | Beta -6.4 | 52 Weeks Range 1.80 - 16.94 | Updated Date 11/29/2025 |
52 Weeks Range 1.80 - 16.94 | Updated Date 11/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.9 |
Earnings Date
Report Date 2025-11-07 | When - | Estimate -0.46 | Actual -0.84 |
Profitability
Profit Margin - | Operating Margin (TTM) -2493.79% |
Management Effectiveness
Return on Assets (TTM) -42.78% | Return on Equity (TTM) -71.42% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 64677938 | Price to Sales(TTM) 14.93 |
Enterprise Value 64677938 | Price to Sales(TTM) 14.93 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.64 | Shares Outstanding 9252719 | Shares Floating 5423111 |
Shares Outstanding 9252719 | Shares Floating 5423111 | ||
Percent Insiders 32.17 | Percent Institutions 23.52 |
Upturn AI SWOT
CervoMed Inc.
Company Overview
History and Background
CervoMed Inc. is a clinical-stage company focused on developing innovative therapies to treat neurological diseases, particularly those associated with aging. Founded in 2018, it aims to address unmet medical needs in conditions like mild cognitive impairment and early Alzheimer's disease.
Core Business Areas
- Drug Development: Focuses on the research and development of novel pharmaceutical products targeting cognitive impairment and neurodegenerative diseases.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
Leadership and Structure
The leadership team consists of experienced executives in the pharmaceutical and biotechnology industries. The organizational structure is typical of a clinical-stage biotech company, with departments focused on research, development, clinical operations, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Neuvivate: Neuvivate is CervoMed's lead drug candidate for the treatment of mild to moderate Alzheimer's disease. It's currently in Phase 2 clinical trials. Competitors include established treatments like Aricept (donepezil) and newer experimental drugs from companies like Biogen and Eli Lilly. Market share data is not available as it is not yet approved for sale.
Market Dynamics
Industry Overview
The market for Alzheimer's disease and related dementias is substantial and growing due to the aging global population. There's a high unmet need for effective treatments that can slow or reverse disease progression.
Positioning
CervoMed Inc. is positioned as a company focused on developing disease-modifying therapies for Alzheimer's disease. It differentiates itself through its specific drug target and mechanism of action.
Total Addressable Market (TAM)
The global Alzheimer's disease market is projected to reach hundreds of billions of dollars in the coming years. CervoMed Inc. is striving to capture a share of this market with its innovative drug development efforts. The estimated total addressable market (TAM) for Alzheimer's therapeutics is over $100 billion, growing rapidly. CervoMed is positioned to address a segment of this TAM pending clinical trial success.
Upturn SWOT Analysis
Strengths
- Novel drug target and mechanism of action
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Early-stage clinical development
- Limited financial resources compared to larger pharmaceutical companies
- High risk of clinical trial failure
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
Threats
- Clinical trial failure
- Competition from other companies developing Alzheimer's drugs
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- LLY
- BIIB
- ABBV
Competitive Landscape
CervoMed Inc. faces intense competition from larger pharmaceutical companies with established resources and marketed products. CervoMed's success depends on demonstrating superior efficacy and safety in clinical trials.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by progress in drug development and expansion of the clinical pipeline.
Future Projections: Future growth is dependent on successful clinical trial outcomes and potential regulatory approvals. Analyst estimates are not readily available due to the early stage of the company.
Recent Initiatives: Recent initiatives include advancing the Neuvivate clinical program and exploring potential partnerships.
Summary
CervoMed is a clinical-stage biotech company targeting Alzheimer's disease. Its success hinges on positive Neuvivate clinical trial results. It faces competition from larger, more established companies. Current revenues are minimal, and future growth is highly dependent on clinical milestones and partnerships. Financial stability is key for ongoing research and development.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Market research reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Data may be estimates and projections, and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CervoMed Inc.
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2016-01-04 | Co-Founder, CEO, President & Director Dr. John J. Alam M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 15 | Website https://www.cervomed.com |
Full time employees 15 | Website https://www.cervomed.com | ||
CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. It is being evaluated in a Phase 2b study in patients with DLB. The company develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.